Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Group in a report released on Tuesday. They presently have a $198.00 price target on the medical research company’s stock. Jefferies Group’s target price would suggest a potential upside of 14.20% from the company’s previous close.

AMGN has been the topic of a number of other reports. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $175.53 price objective on the stock. in a report on Monday, May 30th. Bank of America Corp. reiterated a “hold” rating and issued a $182.00 price objective on shares of Amgen in a report on Wednesday, June 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $186.00 price objective on shares of Amgen in a report on Thursday, June 9th. Leerink Swann reiterated a “market perform” rating and issued a $186.00 price objective on shares of Amgen in a report on Thursday, June 9th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $202.00 price objective on shares of Amgen in a report on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $184.87.

Shares of Amgen (NASDAQ:AMGN) traded up 1.17% during mid-day trading on Tuesday, reaching $173.38. The company’s stock had a trading volume of 2,607,420 shares. The stock has a 50 day moving average of $172.00 and a 200-day moving average of $159.47. Amgen has a one year low of $130.09 and a one year high of $176.64. The stock has a market cap of $129.75 billion, a P/E ratio of 17.74 and a beta of 0.87.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/amgen-inc-amgn-stock-rating-reaffirmed-by-jefferies-group.html

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.57 EPS. On average, equities research analysts expect that Amgen will post $11.36 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were paid a dividend of $1.00 per share. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.31%. Amgen’s payout ratio is currently 40.90%.

In related news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Abner Herrman & Brock LLC increased its position in shares of Amgen by 430.9% in the first quarter. Abner Herrman & Brock LLC now owns 31,136 shares of the medical research company’s stock worth $4,668,000 after buying an additional 25,271 shares during the last quarter. CHICAGO TRUST Co NA increased its position in Amgen by 3.6% in the first quarter. CHICAGO TRUST Co NA now owns 16,902 shares of the medical research company’s stock valued at $2,534,000 after buying an additional 590 shares in the last quarter. DnB Asset Management AS increased its position in Amgen by 69.2% in the first quarter. DnB Asset Management AS now owns 62,366 shares of the medical research company’s stock valued at $9,351,000 after buying an additional 25,500 shares in the last quarter. CENTRAL TRUST Co bought a new position in Amgen during the first quarter valued at about $7,309,000. Finally, Newman Dignan & Sheerar Inc. increased its position in Amgen by 1.5% in the first quarter. Newman Dignan & Sheerar Inc. now owns 10,834 shares of the medical research company’s stock valued at $1,624,000 after buying an additional 156 shares in the last quarter. Hedge funds and other institutional investors own 79.18% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.